, Michal Pyzik 1 , Mario A. Ostrowski 7, 12 , Jonathan N. Glickman 13 , Christopher E. Rudd T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell exhaustion in chronic viral infection and cancers [1] [2] [3] [4] [5] . Under some conditions, TIM-3 expression has also been shown to be stimulatory. Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), is being targeted for cancer immunotherapy, it is important to identify the circumstances under which TIM-3 can inhibit and activate T-cell responses. Here we show that TIM-3 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), another well-known molecule expressed on activated T cells and involved in T-cell inhibition [6] [7] [8] [9] [10] . Biochemical, biophysical and X-ray crystallography studies show that the membranedistal immunoglobulin-variable (IgV)-like amino-terminal domain of each is crucial to these interactions. The presence of CEACAM1 endows TIM-3 with inhibitory function. CEACAM1 facilitates the maturation and cell surface expression of TIM-3 by forming a heterodimeric interaction in cis through the highly related membranedistal N-terminal domains of each molecule. CEACAM1 and TIM-3 also bind in trans through their N-terminal domains. Both cis and trans interactions between CEACAM1 and TIM-3 determine the tolerance-inducing function of TIM-3. In a mouse adoptive transfer colitis model, CEACAM1-deficient T cells are hyper-inflammatory with reduced cell surface expression of TIM-3 and regulatory cytokines, and this is restored by T-cell-specific CEACAM1 expression. During chronic viral infection and in a tumour environment, CEACAM1 and TIM-3 mark exhausted T cells. Co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumour immune responses with improved elimination of tumours in mouse colorectal cancer models. Thus, CEACAM1 serves as a heterophilic ligand for TIM-3 that is required for its ability to mediate T-cell inhibition, and this interaction has a crucial role in regulating autoimmunity and anti-tumour immunity.
We examined the role of CEACAM1 in ovalbumin (OVA)-specific peripheral T-cell tolerance 11 . OVA protein administration (Extended Data Fig. 1a ) resulted in tolerance induction in wild-type OVA-specific T-cell receptor transgenic OT-II Rag2 2/2 mice (Fig. 1a) , but not in transgenic OT-II Ceacam1 2/2 Rag2 2/2 mice (Fig. 1b) . Transfer of carboxyfluorescein diacetate succinimidyl ester (CFSE)-labelled naive CD4 , but not wild-type, mice lacked TIM-3 expression after Staphylococcus aureus enterotoxin B (SEB) administration, suggesting CEACAM1 and TIM-3 co-expression on tolerized T cells (Extended Data Fig. 1e, f) . Flag-tagged human (h) CEACAM1 enhanced cell surface expression of co-transfected haemagglutinin (HA)-tagged hTIM-3 in human embryonic kidney 293T (HEK293T) cells, with virtually all hTIM-3-positive HEK293T cells notably CEACAM1-positive (Fig. 1e) . Human T cells co-expressed TIM-3 and CEACAM1 after in vitro activation with decreased CEACAM1 expression after TIM3 (also known as HAVCR2) silencing ( Fig. 1f and Extended Data Fig. 1g, h ). Human immunodeficiency virus (HIV)-infected, but not uninfected, subjects exhibited increased CEACAM1
1 TIM-3 1 (doublepositive) CD4
1 T cells, which were poor producers of interferon-c (IFNc), as were double-positive CD8 1 T cells (Fig. 1g , h and Extended Data Fig. 1i-l) . In situ proximity ligation analysis 12 of hCEACAM1 and hTIM-3 co-transfected HEK293T cells ( Fig. 1i and Extended Data Fig. 1m-o) , and co-cultures of activated primary human T cells (Extended Data Fig. 1p , q) confirmed the nearness of both molecules on the cell surface of HEK293T cells and co-localization within the immune synapse of activated T cells, respectively.
TIM-3 has been proposed to engage an unknown ligand 13 (Extended Data Fig. 2a-c) , and we considered CEACAM1 a possible candidate that is known to homodimerize 14 . Modelling available X-ray crystallographic structures of mouse (m) CEACAM1 (ref. 14) and mTIM-3 (ref. 13 ) membrane-distal IgV-like, N-terminal domains predicted structural similarity with extensive interactions along their FG-CC9 interface in cis and trans configurations (Extended Data Fig. 2d -g and Supplementary Information). Mouse T-cell lymphoma cells predicted to possess a novel TIM-3 ligand expressed CEACAM1 (refs 13, 15) (Extended Data Fig. 2h, i) . hCEACAM1, but not integrin a5 (ITGA5) (Extended Data Fig. 3a) , was co-immunoprecipitated with hTIM-3 and vice-versa from co-transfected HEK293T cells (Fig. 2a, b) . Co-immunoprecipitation of CEACAM1 and TIM-3 was confirmed with activated primary human T cells (Extended Data Fig. 3b ) and primary mouse T cells from either Ceacam1-4L Tg Ceacam1 2/2 mice 6 or Ceacam1-4S Tg Ceacam1 2/2 mice 10 (transgenic mice in which CEACAM1 isoforms containing a long (L) or short (S) cytoplasmic tail, respectively, are conditionally overexpressed in T cells) 7 (Extended Data Fig. 3c ). Although tunicamycin treatment had no effect (Extended Data Fig. 3d ), mutation of amino acid residues including natural human allelic variants anticipated to be involved in these interactions disrupted the coimmunoprecipitation of hCEACAM1 and hTIM-3 in co-transfected HEK293T cells (Fig. 2c, d , Extended Data Fig. 3e -s, Extended Data Table 1 and Supplementary Information).
A single-chain of the hCEACAM1 N-terminal domain (amino acids 1-107) joined to the hTIM-3 N-terminal domain (amino acids 1-105) by a linker (GGGGS) 4 with a hexahistidine tag appended to the carboxy terminus was expressed in Escherichia coli (Extended Data Fig. 4a ), and shown to interact specifically with the N-terminal domain of hTIM-3 by surface plasmon resonance (Extended Data Fig. 4b-e ). This singlechain protein was crystallized and a structural model built from X-ray diffraction data (Extended Data Table 2 ). This revealed two similar copies of a hCEACAM1 (IgV domain)-hTIM-3 (IgV domain) heterodimer interacting along each of the respective FG-CC9 faces ( Metabolic labelling ( Fig. 2h-j) showed overall enhancement of hTIM-3 biosynthesis after hCEACAM1 co-expression with decreased cell surface display, intracellular accumulation and hypoglycosylation of hTIM-3 when mutant, hypomorphic forms of hTIM-3 or hCEACAM1 were coexpressed in HEK293T cells (Extended Data Fig. 5a -e). Especially profound was a natural hTIM-3 variant (rs147827860 (Thr101Ile)) that although exhibiting normal core protein association with hCEACAM1 (Extended Data Fig. 5f ) could not be rescued by hCEACAM1 co-expression and remained hypoglycosylated with increased intracellular retention and a near absence of cell surface expression (Fig. 2h, i , Extended Data Fig. 5a , b, e and Supplementary Information). CD4 1 T cells from SEB-treated Ceacam1 2/2 mice or mice with transgenic overexpression of Tim3 (also known as Havcr2) in T cells 16 lacking CEACAM1 expression (Tim3 Tg Ceacam1
) exhibited diminished expression of all mTIM-3 forms (fully glycosylated, hypoglycosylated and core protein) (Fig. 2k) , decreased upregulation of TIM-3 expression on the cell surface (Fig. 2l ) and blunted deletion of CD4 1 Vb8 1 T cells (Extended Data Fig. 5g ) relative to wild-type or transgenic Tim3
Tg mice expressing endogenous CEACAM1. T-helper 1 (T H 1) polarized cells from Tim3
Tg Ceacam1 2/2 mice were resistant to galectin-9-induced apoptosis (Extended Data Fig. 5h ), which is dependent on TIM-3 expression as a glycoprotein 15 .
The hTIM-3 N-terminal domain bound hCEACAM1 and stained the cell surface of human CEACAM1-4L-transfected Jurkat T cells ( Fig. 2m and Extended Data Fig. 5i, j) . Trans-ligation of wild-type mouse CD4 1 T cells with a mCEACAM1 N-terminal domain-Fc fusion protein (NFc) rendered them unresponsive to in vitro stimulation with anti-CD3 and anti-CD28 ( Fig. 2n and Extended Data Fig. 5k ). CD4
1 T cells from SEBtreated Tim3 Tg or Tim3 Ceacam1 2/2 mice exhibited similar levels of TIM-3 associated BAT3, a repressor of TIM-3 cytoplasmic tail signalling 17 , at the time of T-cell isolation (Fig. 2o) . However, only T cells from SEBtolerized Tim3
Tg mice, but not SEB-treated Tim3 Tg Ceacam1 2/2 mice that were resistant to SEB-induced tolerance, exhibited BAT3 dissociation from mTIM-3 after NFc fusion protein ligation with further release observed after addition of anti-CD3 ( Fig. 2o and Extended Data Fig. 5l, m) . We observed similar levels of NFc fusion protein staining of primary T cells from Tim3
Tg and Tim3 Tg Ceacam1 2/2 mice, relative to that observed with Ceacam1 2/2 mice, which was blocked by a TIM-3-specific antibody (Extended Data Fig. 5n ), implicating heterophilic ligation of TIM-3 as the major factor responsible for T-cell inhibition and BAT3 release.
Highly activated CD4 1 T cells from wild-type and Ceacam1 2/2 mice were transduced with a retrovirus encoding green fluorescent protein (GFP) plus mTIM-3. Anti-CD3 induced proliferation and TNF-a secretion was inhibited by NFc fusion protein ligation in transduced wildtype but not Ceacam1 2/2 T cells or all groups transduced with GFP alone (Fig. 2p, q and Extended Data Fig. 5o, p) . Both wild-type and Ceacam1
2/2
T-cell transductants with a mTIM-3 cytoplasmic tail deletion construct (TIM-3
D252-281
) 17, 18 were unresponsive to anti-CD3 stimulation or NFc fusion protein ligation (Fig. 2p, q and Extended Data Fig. 5o, p) .
Tolerance pathways are important in T-cell regulation 19 . We detected homozygous rs147827860 (Thr101Ile) carriage in inflammatory bowel disease (IBD) but not controls (Extended Data Table 3a-c). We thus transferred naive CD4 1 CD62L high CD44 2 T cells from wild-type mice into Ceacam1 2/2 Rag2 2/2 recipients and observed colon-infiltrating CEACAM1
1 TIM-3 1 T cells expressing markedly decreased intracellular levels of IFN-c, IL-2 and IL-17A relative to other lamina propria T cells (Fig. 3a, b) . Colon-infiltrating lamina propria T cells from adoptive transfer of naive Ceacam1
recipients expressed reduced cell surface levels of TIM-3 ( Fig. 3c ) and increased intracellular levels of TNF-a (Fig. 3d ) in association with a severe progressive colitis with increased mortality (Fig. 3e , dagger symbol), and histopathological evidence of injury (Fig. 3f ) characterized by 1 T cells after SEB stimulation (h) in HIV infection. C, CEACAM1; T, TIM-3 (n 5 4 per group). i, In situ proximity ligation assay of hCEACAM1 and hTIM-3 co-transfected HEK293T as in e. DAPI, 49,6-diamidino-2-phenylindole. All data are mean 6 s.e.m. and represent five (e, f), three (c, d, i) and two (a, b) independent experiments. *P , 0.05; **P , 0.01; ***P , 0.001.
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acute and chronic inflammation (Extended Data Fig. 6a ). Reestablishment of T-cell-specific mCEACAM1-4L expression using Ceacam1-4L
Tg

Ceacam1
2/2 mice 6 , restored TIM-3 display and decreased intracellular TNF-a expression by the infiltrating lamina propria T cells together with decreased disease severity (Fig. 3c-f and Extended Data Fig. 6b ), reflective of CEACAM1
Tg mice, were hyper-inflammatory after transfer into Ceacam1 2/2 Rag2 2/2 recipients and caused significant weight loss and severe colitis with increased expression of T H 17 signature genes ( Fig. 3g-i and Extended Data Fig. 6c, d ). Nanostring (Extended Data Fig. 6e ) and quantitative PCR (Fig. 3j) Fig. 6f-j) . At 2.5% DSS, Tim3
Tg mice exhibited 100% fatality, significantly greater than all other genotypes (Fig. 4a) . Tumour quantification at a lower DSS dose (1.5%) showed that the polyp numbers, polyp size, high-grade dysplasia and frank carcinoma were significantly higher in Tim3
Tg than in wild-type mice with decreased neoplasia observed in Tim3 Tg Ceacam1 2/2 and Ceacam1 2/2 mice ( After implantation of colorectal cancer cells (CT26) subcutaneously in BALB/c mice, a significant fraction of CD8 1 tumour infiltrating lymphocytes (TILs) was triple-positive T cells (TIM-
, with the relative cell surface levels of TIM-3 correlating with CEACAM1 (Fig. 4e) . PD-1 1 TIM-3 bright CEACAM1 1 T cells were characterized by extremely low intracellular IL-2 and TNF-a expression consistent with exhaustion (Fig. 4f) . Co-administration of an anti-mCEACAM1 and anti-mTIM-3 antibody delayed subcutaneous tumour growth in a preventative model ( Fig. 4g and Extended Data Fig. 7a) , and was able to exceed protection with co-blockade of PD-1 and TIM-3 (Extended Data Fig. 7b, c) . In a therapeutic model, blockade of CEACAM1 synergized with PD-1 inhibition (Extended Data Fig. 7d, e) . CEACAM1 and TIM-3 co-blockade was associated with increased CD8 1 (Fig. 4h ) and CD4
1
( Fig. 4i ) TILs with enhanced IFN-c production ( Fig. 4j ) and decreased IL-10 production (Extended Data Fig. 7f ) by the infiltrating CD8 1 and CD4 1 T cells, respectively. Increased tumour antigen-specific CD8 T cells defined by AH1-tetramer staining 23 , relative to the total CD8 1 T-cell population ( Fig. 4k and Extended Data Fig. 7g ) was observed in the draining lymph nodes that correlated with tumour growth inhibition (Extended Data Fig. 7h ). CT26 tumour growth was impeded in Ceacam1 2/2 mice (Fig. 4l ) in association with increased AH-1 tetramer (q) mice transduced with wild-type mTIM-3 (Tw), mTIM-3 D252-281 (Tmut) or vector exposed to anti-CD3 and either NFc or IgG1-Fc (IgG1). Data are mean 6 s.e.m. and represent five (a, b), four (c, d), three (h-j, l, n, p, q) and two (k, m, o) independent experiments. NS, not significant; *P , 0.05; **P , 0.01; ***P , 0.001.
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CD8
1 T cells in draining lymph nodes ( Fig. 4m and Extended Data Fig. 7i ) and decreased TIM-3 expression on tumour-associated TILs (Fig. 4n) .
In conclusion, we show that CEACAM1 and TIM-3 form a new heterodimeric complex that is determined by interactions between their structurally similar membrane-distal IgV-like, N-terminal domains. This association is evident during early biosynthesis and crucial for proper maturation, cell surface display and function of TIM-3 and probably CEACAM1 when expressed together. CEACAM1 also functions as an essential trans-heterophilic ligand for TIM-3 with the tolerance-inducing functions of TIM-3 requiring interactions with CEACAM1 in both cis and trans configurations. CEACAM1 expression with TIM-3 is further a b
No. of indicated sizes of polyps 
) CD8
1 T cells in draining lymph nodes (dLN) (k) in groups described in g. l-n, Growth of CT26 cells (l), AH1 tet 1
CD8
1 T cells in dLN (m) and TIM-3 expression on TILs (n) in wild-type and Ceacam1 2/2 mice. Data are mean 6 s.e.m. and represent four (e), three (g-k) and two (a-d, f, l-n) independent experiments. *P , 0.05; **P , 0.01; ***P , 0.001. 
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characteristic of T cells with an exhausted phenotype such that in the absence of these interactions inflammatory responses are unrestrained and anti-tumour immunity enhanced. Together, these studies describe a novel class of heterodimeric protein interactions that function in tolerance induction with broad implications for many types of infectious, autoimmune and neoplastic conditions.
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Mice. C57BL/6 and BALB/c mice were purchased from Jackson Laboratory. 6, 10 . All studies were performed in mice with a C57BL/6 genetic background except for CT26 tumour experiments that were in a BALB/c genetic background. Animal studies were conducted in a gender and age-matched manner for all experiments. Both male and female mice were used and were 6-8 weeks of age at the time of experiments or 6-10 weeks for the adoptive transfer colitis experiments. The number of animals used per group was based on previous experimental results and observed variability. Histopathology analysis was performed in a blinded manner by an expert pathologist (J.N.G.). For all other in vitro and in vivo analyses, investigators were not blinded to treatment allocation. All experiments were approved and conducted according to the guidelines set forth by the Harvard Medical Area Standing Committee on Animals. Genotyping. Mouse tails were digested in tail lysis buffer (100 mM Tris-HCl, pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl and proteinase K (Roche)) overnight at 55 uC. Genomic DNA was phenol-extracted and isopropanol precipitated. DNA was dissolved in TE buffer. The primer sequences for genotyping are available on request. T-cell tolerance animal models. For SEB tolerance induction model, animals of the indicated genotypes were injected intraperitoneally with 25 mg of SEB (Millipore) on days 0 and 4, and euthanized at day 8 after the first injection. Peripheral lymph node cells were isolated and stained for T-cell receptor Vb6, Vb8 and CD4, and analysed for TIM-3 and CEACAM1 expression on CD4
1 Vb8 1 cells. Cells were also re-stimulated in vitro at 0.5 3 10 6 cells per ml with anti-CD3 (0.1-10.0 mg ml
21
) and assessed for proliferation by [ 3 H]-thymidine (1 mCi ml 21 ) uptake or production of IL-2 by ELISA. For OVA antigen-specific T-cell tolerance induction, highdose OVA antigen was used and modified according to previous studies 11, 25, 26 . In brief, transgenic OT-II Rag2 2/2 or Ceacam1 2/2 Rag2 2/2 mice were injected intraperitonally with 500 mg of OVA peptide (323-339, 323-ISQAVHAAHAEINEAGR-329, AnaSpec) in an equal volume amount of complete Freund's adjuvant (CFA) or PBS alone at day 0 (activation of immune response) and at day 4 (tolerance induction). At day 10, CD4
1 T cells were isolated from spleens and pooled peripheral lymphocytes from each experimentally treated mouse as indicated above. The pooled lymphocytes from each mouse were re-stimulated in vitro with various concentrations of OVA 323-339 peptide (0.1, 1, 2.5 and 10 mg ml were injected intravenously by tail vein into syngeneic C57BL/6 wild-type or Ceacam1 2/2 recipients. After 18 h to allow the adoptively transferred T cells to establish themselves in vivo, and which showed no differences in parking of the T cells among the various genotypes, the mice were then immunized with OVA 323-339 (50 mg) in an equal volume of CFA. On day 3, cells were collected from spleen, mesenteric lymph and peripheral lymph node of individual mice and stained with DAPI to exclude dead cells, and concurrently stained with anti-CD4-PerCp, anti-CEACAM1-allophycocyanin and anti-TIM-3-phycoerythrin. Total lymphocytes were gated and the CFSE subset representing the transgenic OT-II, adoptively transferred CD4 1 T cells analysed and CEACAM1-and TIM-3-expression assessed on the CFSE-positive cells. Cell lines. 3T3 mouse fibroblast cells, the TK-1 mouse T cell lymphoma cell line, the HEK293T cell line, and CT26 mouse colorectal cancer cell lines were all purchased from ATCC as mycoplasma-free cell lines and culture conditions were all followed according to ATCC instructions. Human CEACAM1-4L transfected human Jurkat T-cell line and human CEACAM1-4L transfected HeLa cells have been previously described (provided by J. Shively and S. G. Owen) 28, 29 . Antibodies and reagents. An anti-CEACAM1 monoclonal antibody that binds to the C-C9 loop of mCEACAM1 (ref. 30) (cc1, provided by K. V. Holmes and J. Shively) and isotype control (mouse IgG1) antibodies for the in vivo injection experiments were purchased from Bio X Cell. An Fc fusion protein consisting of the N-terminal domain of mouse CEACAM1 together with human IgG1, N-CEACAM1-Fc 31 was provided by T. Gallagher. The following fluorochrome-conjugated antibodies were purchased from BioLegend: anti-IFN-c (XMG1.2), anti-IL-2 (JES6-5H4), anti-IL-17A (TC11-18H10.1), anti-IL-10 (JES5-16E3) and PD-L1 (10F.9G2); and other antibodies were purchased from eBioscience: anti-CD3 (clone, 145-2C11), anti-CD28 (clone 37.51), anti-CD8a (clone, 53-6.7), anti-CD4 (clone, RM4-5), anti-TNF-a (clone, MP6-XT22) and anti-TIM-3 (clone, 8B.2C12). The BAT3 antibody (clone AB10517) was purchased from Millipore. Brefeldin A and monensin were from eBioscience. The anti-TIM-3 5D12, 2C12, 2E2, 2E12 and 3F9 antibodies were generated in V.K.K.'s laboratory and 5D12 was conjugated to phycoerythrin and allophycocyanin by BioLegend. The anti-human CEACAM1 antibodies specific for the N-terminal domain (34B1, 26H7 and 5F4) have been previously described and characterized in R.S.B.'s laboratory 32, 33 . All the antibodies used for biochemical experiments if otherwise indicated, were purchased from Cell Signaling. Tunicamycin was purchased from Sigma. Primary human T-cell isolation. Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats from healthy anonymous donors according to an Institutional Review Board approved protocol from Brigham and Women's Hospital. CD4
1 T cells were purified from PBMC using CD4 Microbeads (Miltenyi) and cultured in RPMI-1640 supplemented with 10% FBS (Invitrogen), L-glutamine, non-essential amino acids, sodium pyruvate, 20 mM HEPES and 100 IU ml 21 recombinant human IL-2 (R&D Systems). The T cells were stimulated with plate-bound anti-CD3 (OKT3) and anti-CD28 (CD28.2) antibodies (1 mg ml 21 each, eBioscience). Cellular based studies on HIV-infected individuals. In the analysis of HIV-infected individuals, informed consent was obtained in accordance with the guidelines for conduction of clinical research at the University of Toronto and Maple Leaf Clinic institutional ethics boards. Written informed consent was provided for this study, which was reviewed by research ethics board of the University of Toronto, Canada and of St. Michael's Hospital, Toronto, Canada. Individuals were recruited from a Toronto-based cohort (Maple Leaf Clinic and St. Michael's Hospital, Toronto, Canada). Samples were obtained from HIV-positive chronically infected antiretroviral treatment naive individuals (infected .1 year, with detectable viral load) and demographically matched HIV-seronegative individuals. Whole blood was collected in anti-coagulant treated tubes and PBMCs were isolated using Ficoll-Paque PLUS (GE Healthcare Bio-Sciences) and stored at 2150 uC until future use. PBMCs from healthy HIV-1-uninfected and HIV-1-infected individuals were stained with CEACAM1 monoclonal antibody (clone 26H7), detected with a fluorophore-conjugated secondary antibody, followed by fluorophore-conjugated monoclonal antibodies to CD4, CD8 and CD3 (BioLegend), and TIM-3 (R & D Systems) to determine phenotype assessment. An Aqua amine dye (Invitrogen) was used to discriminate live and dead cells. For functional experiments, cells were stimulated after thawing with 1 mg ml 21 of overlapping HIV-1 Clade B Gag peptide pool (National Institutes of Health AIDS Reagent Program), or 1 mg ml 21 SEB (Sigma Aldrich) in the presence of brefeldin A (Sigma) for 6 h. Surface staining was followed by a fixation and permeabilization step. Intracellular staining for cytokines was performed using anti-IFN-c (Biolegend). Cells were fixed in 2% formalin/PBS and acquired with a modified LSRII system (BD Biosciences). A total of 100,000 events were collected and analysed with FlowJo software (Tree Star). In situ proximity ligation assay. Proximity ligation assay was performed using Duolink in situ PLA reagents on HEK293T cells co-transfected with human CEACAM1-Flag-tagged and human TIM-3-HA-tagged vectors. Primary antibodies used were anti-Flag or anti-HA antibodies and followed by secondary antibodies. Cells on slides were blocked with Duolink Blocking stock followed by the application of two PLA probes in 13 antibody diluent. The slides were washed in a wash buffer (13 TBS-T) for 5 min twice and processed for hybridization using Duolink Hybridization stock 1:5 in high purity water and followed by incubation for 15 min at 37 uC. Duolink Ligation was performed with ligase and the slides were incubated in a preheated humidity chamber for 15 min at 37 uC. Amplification was then achieved using Duolink Amplification stock containing the polymerase and the slides were incubated again in a pre-heated humidity chamber for 90 min at 37 uC. 
In some experiments, 6 h after transfection, transfected cells were treated with 2 mg ml 21 or 10 mg ml 21 tunicamyin provided in DMSO for the last 24 h of transfection. Transfected cells were washed once with cold PBS and lysed on ice with 0.5 ml of immunoprecipitation buffer containing 20 mM Tris-HCl, 0.15 M sodium chloride, pH 7.6, with protease inhibitor cocktail tablets (Roche) and 1.0% digitonin (Sigma). After 60 min, the cell lysates were spun at 14,000 r.p.m. for 30 min at 4 uC. The lysate was subsequently incubated with 5 ml of protein A-Sepharose (Sigma) that had been pre-adsorbed with an equal volume of immunoprecipitation buffer followed by three 1-h incubations with protein A-Sepharose. The pre-cleared lysates were incubated for 2 h at 4 uC with 10 ml of protein A-Sepharose beads bound to the specific antibodies. Some immunoprecipitates were incubated with agarose-HA antibody. The control and specific immunoprecipitates were washed with immunoprecipitation buffer and re-suspended in 30 ml of Laemmli sample buffer without reducing agents. After boiling for 5 min, the proteins were resolved by SDS-PAGE in regular Tris-glycine buffer on a 4-20% Tris-Glycine Gel (Novex). The proteins were electrically transferred to a PVDF (polyvinylidene difluoride) membrane. After blocking with 5% skim milk in 0.05% PBS-Tween (PBS-T), the membranes were incubated for 12 h at 4 uC with primary antibodies. The membranes were further incubated with corresponding secondary antibodies for 1 h at room temperature and visualized by Amersham ECL Western Blotting Detection Reagents (GE Healthcare). The specific antibodies used for immunoprecipitation and immunoblotting in this assay were anti-Flag antibody produced in rabbit (Sigma), HA.11 (16B12) (Covance), anti-HA-Tag-agarose (MBL, Medical & Biological Laboratories Co), anti-HA antibody produced in rabbit and in mouse (Sigma) and anti-human CEACAM1 antibody, 5F4. Unsaturated films were digitally scanned and band intensities (densitometric analysis) were quantified using ImageJ (NIH).
Co-immunoprecipitation of primary T cells. Primary human CD4
1 T cells were purified and activated with plate bound anti-CD3 (1 mg ml
21
) and anti-CD28 (1 mg ml
) in the presence of recombinant (r) IL-2 (10 ng ml
; NIH) for 5 days. Cells were then rested in rIL-2 containing (10 ng ml 21 ) complete medium for 3 days and re-stimulated with soluble anti-CD3 (1 mg ml
) for 2 days. Cell lysates were prepared as above and treated with N-glycanase by the manufacturer's suggested protocol (Promega). N-glycanase treated lysates were immunoprecipitated with anti-human TIM-3 antibodies (2E2, 2E12 and 3F9) or mouse IgG1 as control and the immunoprecipitates subjected to SDS-PAGE and transferred to PVDF membranes followed by immunoblotting with the mouse anti-human CEACAM1 monoclonal antibody, 5F4, as described above. Primary mouse splenocytes were prepared from Ceacam1-4L Tg Ceacam1 2/2 and Ceacam1-4S Tg Ceacam1 2/2 mice and cultured in the presence of anti-CD3 (1 mg ml 21 ) or anti-CD3 (1 mg/ml 21 ) plus anti-CD28 (1 mg ml
) or medium only for 96 h. Cell lysates were prepared, immunoprecipitated with cc1 (anti-mCEACAM1) and immunblotted with 5D12 (anti-mTIM-3) monoclonal antibodies as described above. Pulse-chase experiments, immunoprecipitation, endoglycosidaseH digestion and SDS-PAGE. Cells were transfected as above with wild-type human HA-tagged hTIM-3 or Thr101Ile variant of HA-tagged hTIM-3 with or without co-transfection with Flag-tagged human CEACAM1 vector. All transfections included a co-transfection with Flag-tagged influenza virus M2 protein (M2) encoding vector as a non-binding control. After 48 h, transfected HEK293T cells were incubated with methionineand cysteine-free DMEM for 30 min at 37 uC. Cells were labelled with 10 mCi ml ; PerkinElmer Life Sciences) at 37 uC for the indicated times and chased with DMEM at 37 uC for the indicated times. Cells were lysed in Nonidet P-40 lysis buffer (50 mM Tris, pH 7.4, 0.5% Nonidet P-40, 5 mM MgCl 2 , and 150 mM NaCl). Immunoprecipitations were performed using 30 ml of anti-HA agarose (Roche) for 2 h at 4 uC with gentle agitation. For enzymatic digestions, immunoprecipitates were denatured in glycoprotein denaturing buffer (0.5% SDS, 1% 2-mercaptoethanol) at 95 uC for 5 min, followed by addition of sodium citrate (pH 5.5) to a final concentration of 50 mM, and incubated with endoglycosidaseH (New England Biolabs) at 37 uC for 2 h. Immune complexes were eluted by boiling in reducing sample buffer, subjected to SDS-PAGE (10%), and visualized by autoradiography. Densitometric quantification of radioactivity was performed on a PhosphorImager (Fujifilm BAS-2500) using Image Reader BAS-2500 V1.8 software (Fujifilm) and Multi Gauge V2.2 (Fujifilm) software for analysis. Quantification of human TIM-3 in pulse-chase metabolic labelling was calculated by the following formula representing the average of 2-4 data sets: (human TIM-3 signal intensity 2 M2 protein signal intensity/M2 protein signal intensity). Transduction of primary human T cells with shRNA lentiviral vectors to silence human TIM-3. Lentiviral vectors encoding short hairpin RNAs (shRNAs) (pLKO.1) targeting human TIM3 and a control shRNA targeting lacZ were obtained from the Dana Farber DNA Resource Core. Lentiviral particles were produced as previously described 36 . Primary human CD4
1 T cells were transduced 3 days after stimulation and selected with 2 mg ml 21 puromycin (Sigma) for 5 days followed by gradual increases of puromycin (5 mg ml
) for the next 5 days and re-stimulated with anti-CD3 and CD28 for an additional 5 days. TIM3 shRNA 1 (TRCN0000158033, 59-C GTGGACCAAACTGAAGCTAT-39); TIM3 shRNA 2 (TRCN0000154618, 59-G CACTGAACTTAAACAGGCAT-39); TIM3 shRNA 3 (TRCN0000157816, 59-C AAATGCAGTAGCAGAGGGAA-39); lacZ control knockdown (TRCN0000072225; 59-CTCTGGCTAACGGTACGCGTA-39).
Transduction of primary mouse T cells with retroviral vectors. For transduction of mouse primary CD4
1 T cells, previously described mouse TIM-3 and its mutant expressing retroviruses were prepared in HEK293T cells using eco and gag/pol viral envelope constructs (Clontech Inc.) 17, 37, 38 . Viral supernatants were collected 48 h after transfection and centrifuged and filtered with a 0.45-mm filters. CD4
1 T cells were prepared at 10 6 cells per ml in the presence of polybrene (Sigma; 8 mg ml
21
).
Viral particles and CD4
1 T cells were co-incubated by spin inoculation at 2,000g for 60 min on two sequential days. To detect ectopic expression of the constructs in T cells, cells were allowed to rest for 3 days in 2 ng ml 21 IL-2 and sorted to obtain cells with the highest (45%) GFP expression. Sorted cells were titrated into in vitro T-cell assays. Galectin-9 induction of apoptosis. Naive CD4 1 T cells were polarized under T H 1 inducing conditions. In brief, naive CD4 1 T cells (2 3 10 6 per ml) were stimulated with plate-bound anti-CD3 specific antibodies (10 mg ml
21
) for 48 h. Soluble anti-CD28 antibodies (1 mg ml 21 ), recombinant (r) IL-2 (10 ng ml 21 , NIH) and blocking antibodies to IL-4 (10 mg ml
) and rIL-12 (5 ng ml 21 ) were added and the cells cultured for 7 days. Cells were washed and treated with galectin-9 (2 mg ml 21 ; eBioscience) for 8 h to induce apoptosis. Apoptosis was detected by flow cytometry using apoptosis staining kit (Roche) that stains for annexin V and propidium idodide. Protein purification, crystallization, X-ray data collection and model determination. Competent E. coli BL21 DE3 cells were transformed with a pET9a vector carrying a gene insert coding for a single-chain of a protein consisting of the human CEACAM1 IgV domain (residues 1-107), a 20 amino acid linker (4 repeats of a Gly-Gly-Gly-Gly-Ser motif), and the human IgV domain of TIM-3 (residues 1-105) with a hexa-histidine tag appended to the C terminus. To express the protein, transformants were grown in 1 litre of LB broth under antibiotic selection and induced with 0.1 mM isopropyl-b-D-thiogalactoside (IPTG) after reaching an absorbance at 600 nm (A 600 nm ) of approximately 0.8. Cells were grown for an additional 16 h at 18 uC and collected by centrifugation. Protein was purified from inclusion bodies, which were solubilized in a chaotropic buffer and refolded in a buffer containing 200 mM Tris, pH 8.5, 0.4 M arginine-HCl, 2 mM EDTA, 5 mM cysteamine and 0.5 mM cystamine, as reported previously 39 . Refolded protein was loaded onto a Ni-NTA affinity column and washed several times with a buffer containing 50 mM HEPES, pH 7.5, 300 mM NaCl, 2.5 mM CaCl 2, 10% glycerol and 10-30 mM imidazole. The protein was eluted with 50 mM HEPES buffer, pH 7.2, 300 mM NaCl, 2.5 mM CaCl 2, 10% glycerol and 300 mM imidazole. Eluted protein fractions were analysed by SDS-PAGE, pooled, concentrated and further purified with a Superdex 75 gel filtration column (GE Healthcare) in a buffer containing 50 mM HEPES buffer, pH 7.5, 200 mM NaCl, 2.5 mM CaCl 2 and 10% glycerol. Circular dichroism
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was conducted to confirm proper protein folding. Purified protein (purity .95%, estimated by SDS-PAGE) was concentrated to 2.5 mg ml 21 for crystallization. The initial crystal growth trials were performed by vapour diffusion using a Phoenix robotic system (Art Robbins) with Index Screens 1 and 2 (Hampton Research) and optimized using an additive screen (Hampton Research). Optimized crystals were formed in 4 ml drops (2 ml protein, 2 ml mother liquor), equilibrated against a mother liquor containing 100 mM Tris 8.0 and 25% PEG 3350, at room temperature in a sitting drop setup. For data collection, crystals were cryoprotected in solution containing 25% PEG 3350 and 12% glycerol. X-ray data were collected using the X25 beamline at the National Synchrotron Light Source (NSLS). The data were processed with Mosflm 40 and the CCP4 software suite 41 . A crystallographic model of the single-chain human CEACAM1-TIM-3 protein was built by a molecular replacement strategy using a search model made by modifying published structures of the IgV (N) domain of human CEACAM1 (Protein Data Bank (PDB) code 2GK2) and mouse TIM-3 (PDB code 2OYP). Specifically, all residues were changed to alanine to reduce model bias and all small molecule ligands, water and metals were removed. Molecular replacement was performed with the program Molrep. Model building and structural refinement were performed with the PHENIX software 42 and COOT 43 , respectively. Five per cent of the total reflection data were excluded from the refinement cycles and used to calculate the free R factor (R free ) for monitoring refinement progress. Repeated rounds of model building and refinement with group B-factors refinement strategy and Torsion-NCS restraints resulted in a final crystallographic R work /R free of 34.5%/37.3% using all data to 3.4 Å resolution. The X-ray data and refinement statistics are shown in Extended Data Table 2 . Most of the residues were well defined and verified by PDB validation report (data not shown). However, the b-strands associated with the hTIM-3 AB-ED (ref. 13 ) face did not show the secondary structure of b-sheet formation, and two disulphide bonds (Cys 32-Cys 110 and Cys 53-Cys 62) observed in the mouse TIM-3 structure were missing from the resolved structure. A 2F o 2 F c electron density map of the human CEACAM1 (IgV)-TIM-3 (IgV) single chain was calculated using PHENIX. All the figures were drawn using PyMOL (The PyMOL Molecular Graphics System, Schrödinger, LLC) and labels were added using Adobe Photoshop. Protein purification, crystallization, data collection and structure determination of CEACAM1 (IgV). Competent E. coli BL21 DE3 cells were transformed with a pET9a vector carrying the human CEACAM1 IgV domain gene insert with a N-terminal GST tag. To express the protein, transformants were grown in 1 litre of LB broth under antibiotic selection and induced with 0.1 mM IPTG after reaching an A 600 nm of approximately 0.8. Cells were grown for an additional 16 h at 18 uC and collected by centrifugation. Cell pellets were suspended in 20 mM Tris-HCl buffer, pH 7.5, containing 150 mM NaCl and 10% glycerol, and lysed by sonication. After centrifugation, supernatant was loaded onto a GST column (GE Healthcare) and washed several times with 50 mM Tris-HCl buffer, pH 7.5, containing 150 mM NaCl, 2.5 mM CaCl 2 , 0.1% Triton X-100, and 10% glycerol. After on-column removal of the GST affinity tag with thrombin, protein was eluted with 25 mM Tris-HCl buffer, pH 7.5, containing 200 mM NaCl, 2.5 mM CaCl 2 and 10% glycerol. Eluted protein fractions, as judged by SDS-PAGE, were concentrated and purified through a Superdex 75 gel filtration column (GE Healthcare) by FPLC system with a buffer containing 50 mM Tris-HCl buffer, pH 7.5, containing 200 mM NaCl, 2.5 mM CaCl 2 and 10% glycerol. A single peak for human CEACAM1 IgV domain was collected and the protein was concentrated to 5 mg ml 21 for crystallization. A purity of .95%, was verified by SDS-PAGE.
The initial crystal growth trials were performed in a 96-well format using a Phoenix robotic system (Art Robbins) with Index Screens 1 and 2 (Hampton Research) at room temperature. Optimized crystals were formed in well solution containing 60% Tascimate, pH 8, and 1% b-octyl glucoside at room temperature. For data collection, crystals were cryoprotected in solution containing 60% Tascimate, pH 8 and 18% glycerol. X-ray data were collected using beamline X6A at the National Synchrotron Light Source (NSLS). The data were processed with Mosflm 40 and the CCP4 software suite 41 . The structure of the human CEACAM1 N (IgV) domain was determined by the molecular replacement method using a modified N-terminal domain of human CEACAM1 as a search model (PDB code 2GK2) as the starting model, with all residues changed to alanine to reduce model bias and all small molecule ligands, water and metals were removed. Molecular replacement was performed with Molrep, refinements were performed with PHENIX 42 and intermittent model building was performed with COOT 43 , as described above. Subsequent refinements cycles and model building with individual B-factors and Torsion-NCS restraints strategy led to the final crystallographic R work /R free of 20.3%/24.2% using all data to 2.0 Å resolution. Electron densities were also identified for bound molecules of beta-octyl glucoside and malonic acid. The X-ray data and structure refinement statistics are shown in Extended Data Table 2 . All residues were well defined and verified by PDB validation report (data not shown). A 2F o 2 F c electron density map was calculated using PHENIX 42 .
Structural modelling of CEACAM1-TIM-3 interactions. To model potential interactions between CEACAM1 and TIM-3, superimposition data as shown in Extended Data Fig. 2d , e, of previously described immunoglobulin-variable (IgV) domains of mouse CEACAM1 14 (PDB code 1L62) and mouse TIM-3 (PDB 2OYP) 13 was generated in Pymol (The PyMOL Molecular Graphics System, Schrödinger, LLC), which revealed structural similarity as shown by a score of 2.42 by root mean square deviation (r.m.s.d.) analysis as calculated by Pymol 44 . In addition, multiple sequence alignments were performed using ClustalW 45 . From this analysis, we considered mouse CEACAM1 and TIM-3 as structurally similar proteins. Furthermore, as previous structural data for mouse CEACAM1 supported the formation of CEACAM1 homodimers between its N-terminal domains 14 , and given our evidence that mouse CEACAM1 and TIM-3 are highly similar, we further reasoned that mouse TIM-3 and its human orthologue might heterodimerize with CEACAM1 through their membrane-distal N-terminal domains. This hypothesis was modelled by us in the following manner. We aligned CEACAM1 symmetrically for cis modelling and asymmetrically for trans modelling along the five amino acid residues within the FG-CC9 loops of mTIM-3 as reported previously 13 that describe putative docking sites for an unknown ligand for mouse TIM-3. The ROSIE Docking Server was used to analyse the docking (http://rosettadock.graylab.jhu.edu/ documentation/docking) 46, 47 . We identified the ten best scoring structures from the run in rank order by energy. The top two in cis and the best in trans are shown in Extended Data Fig. 2g . The score (y axis) indicates the energy of the models (the lower the better). The r.m.s. (x axis) indicates the RMS values between the input and output docking models. The docking models identified were further assessed in PyMOL to determine whether the models identified predicted hydrogen bonding within the putative mouse CEACAM1-TIM-3 interface. On the basis of this we identified potential amino acids that may have an important role in mouse CEACAM1-TIM-3 binding, which is summarized in the table associated with Extended Data Fig. 2g .
We used the amino acids of mouse CEACAM1 and mouse TIM-3 modelled at the interface between these two proteins to predict potential contact sites for the human orthologues of CEACAM1 and TIM-3. Furthermore, we searched human exomic databases for allelic variants in these predicted human amino acids. Finally, we used all of this information to make structural modifications of human CEACAM1 and TIM-3 by site-directed mutagenesis to biochemically examine our hypothesis and confirm this by X-ray crystallographic analysis of a human CEACAM1-TIM-3 single-chain protein.
IBD case-control samples and genotyping. German Crohn's disease and ulcerative colitis patients were recruited at the Department of General Internal Medicine of the Christian-Albrechts-University Kiel and Charité Universitätsmedizin Berlin, or nationwide with the support of the German Crohn and Colitis Foundation and the Bundesministerium für Bildung und Forschung (BMBF) competence network 'IBD' (Extended Data Table 3a ). The patients were classified according to clinical, radiological, histological and endoscopic (that is, type and distribution of lesions) according to accepted criteria 48, 49 . Healthy control individuals were obtained from the popgen biobank 50 . All controls were drawn from a population-representative sample. Given the low prevalence of both Crohn's disease and ulcerative colitis and the fact that all control individuals self-reported to have neither Crohn's disease nor ulcerative colitis, control individuals were designated 'healthy'. Written, informed consent was obtained from all study participants and all protocols were approved by the institutional ethical review committees of the participating centres. The variants described in Extended Data Table 3b were genotyped using the Sequenom iPlex and the Life Technologies Taqman system. rs147827860, the single nucleotide polymorphism encoding the hypomorphic Thr101Ile allele of TIM3, is a rare variant with a minor allele frequency of 0.004 in individuals of European descent predicting homozygous carriage with a frequency of 0.000016 (or 1:62,500). None of the publicly accessible databases lists any homozygous occurrences of this variant. Association in the case-control data was tested with Haploview 4.2 (ref. 51 ). An exact test for Hardy-Weinberg equilibrium was performed using the DeFinetti program (Strom, T. M. & Wienker, T. F., http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). Purification of IgV domain of human TIM-3. The TIM-3 IgV domain was expressed with a C-terminal GST tag as inclusion bodies from pET9a in E. coli BL21 DE3 cells. Inclusion bodies were refolded as described previously in refolding buffer containing 200 mM Tris, pH 8.5, 0.4 M arginine-HCl, 2 mM EDTA, 5 mM cysteamine and 0.5 mM cystamine 39 . Refolded proteins were purified by affinity and gel filtration chromatography. The proteins were maintained in a solution containing 25 mM HEPES buffer, pH 7.2, containing 200 mM NaCl, 2.5 mM CaCl 2 and 5% glycerol. Circular dichroism was conducted to ascertain proper protein folding. A purity of .95%, was verified by SDS-PAGE. GST protein pull-down assays. Glutathione-S-transferase (GST) pull-down analyses 52 of the interaction between IgV domains of human TIM-3 and human CEACAM1 were performed in the following manner. The GST-hTIM-3 protein was stored in refolding buffer, and buffer-exchanged with PBS before performing the assay. The
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IgV domain of GST-hTIM-3 proteins were coupled to the glutathione-agarose column following the manufacturer's instructions (Thermo scientific) and in-columnincubated with HEK293T cell lysates derived from cells transfected with Flag-tagged human CEACAM1. The columns were washed extensively and bound proteins were eluted by glutathione. Eluted protein complexes were immunoblotted for the detection of CEACAM1 (immunoblot with anti-Flag) and TIM-3 (immunoblot with anti-GST). TIM-3 ligand precipitation assays. Extracellular membrane-associated proteins on live TK-1 cells were labelled with biotin (EZ-Link Sulfo-NHS-LC-Biotin; Pierce). Whole-cell lysates were prepared and were incubated with 5 mg human IgG, full length TIM-3-Ig or soluble (s)TIM-3-Ig in the presence of protein G-agarose beads (Roche). Beads were washed and boiled with 13 SDS-PAGE loading buffer. Supernatants were collected by centrifugation, and half of each was digested with PNGase F (New England Biolabs). Samples were separated by SDS-PAGE and the TIM-3-Ig fusion protein-specific binding proteins were detected by immunoblot or sliver staining. Mouse model of IBD 53 . Splenic mononuclear cells were obtained from female wildtype, Ceacam1
Tg /wild-type) mice and CD4 1 T cells were isolated using anti-CD4 (L3T4) MACS magnetic beads (Miltenyi Biotec) according to the manufacturer's instructions. Enriched CD4
1 T cells (94-97% pure as estimated by FACS) were then labelled with PerCP-conjugated anti-CD4, allophycocyanin-conjugated anti-CD44, and FITC-conjugated anti-CD62L and phycoerythrin-conjugated anti-TIM-3 (5D12 or 2C12). Subpopulations of CD4
1 T cells were identified by three-colour sorting on a FACSAria (Becton Dickinson). All populations were defined as naive and 98.0% pure on re-analysis. To induce chronic colitis in animals, 5 3 10 5 CD4 1 CD44 lo CD62L high (naive) T cells were adoptively transferred intraperitoneally into 6-10-week-old Ceacam1 2/2 Rag2 2/2 recipient mice. Weights were measured every week, and mice were euthanized by CO 2 for histological evaluation of colitis and lamina propria mononuclear cells. Owing to the severity of colitis associated with adoptive transfer of naive Ceacam1 2/2 CD4 1 T cells, significant mortality was observed resulting in unequal group size at the at the time of culling necessitating post-hoc correction in the statistical analysis (see 'statistical methods'). Colorectal carcinogenesis models. To examine the effect of CEACAM1 and TIM-3 on tumour incidence and multiplicity in an inflammation induced colorectal cancer model, mice were intraperitoneally injected at 6 weeks of age with the carcinogen AOM (Sigma-Aldrich) at 10 mg kg 21 body weight as previously reported 54, 55 . One week later, the mice were started on the first of two 21-day DSS cycles, consisting of a period of 7 days with the tumour promoter DSS at 2.5% or 1.5% in the drinking water followed by 7 days of receiving regular water. Mice showing signs of morbidity were culled. Colons were removed and flushed with PBS buffer and cut longitudinally. Colon tissue sections were either paraffin-embedded for immunohistochemistry or analysis of lamina propria mononuclear cells associated with the tumours. CT26 colorectal carcinoma cells were diluted into 10 3 10 6 cells per ml of PBS. After shaving, either wild-type or Ceacam1 2/2 mice received 200 ml of the CT26 cell suspension subcutaneously in the left flank. All antibody treatments were applied intraperitoneally into the right flank according to the schedules described in Extended Data. Two-hundred micrograms of each antibody or its isotype control were administered according to the schedules described (CEACAM1, cc1 clone; TIM-3 5D12 clone; PDL1, 10F.9G2) Tumour growth was assessed three times per week at 7 days after tumour inoculation by measuring the width and length of the tumours (mm) using calipers and the areas defined (mm 2 ; width 3 length). Mice were euthanized on the basis of the extent of tumour growth observed in the isotype antibody treated control animals to minimize animal suffering in accordance with the approved animal protocol. Histopathological examination of colitis and colitis-associated colorectal cancer. Colons were removed from mice after termination and dissected free from the anus to the caecum. Colonic contents were removed and colons cleaned with PBS before fixation in 4% paraformaldyhyde or 10% neutral buffered formalin followed by routine paraffin embedding. After paraffin embedding, 0.5-mm sections were cut and stained with haematoxylin and eosin. Sections were examined and colitis was scored in a blinded fashion (with respect to genotype and experimental protocol) by one of the authors (J.N.G.). Each of four histological parameters for the severity of colitis was scored as absent (0), mild to severe (1-6): mononuclear cell infiltration, polymorphonuclear cell infiltration, epithelial hyperplasia, epithelial injury and extent of inflammation, modified from a previous study 56 . For AOM/DSS, colitis-associated colorectal cancer studies, an expert pathologist (J.N.G.) examined all tissues for dysplasia, adenoma, low-to-high-grade adenoma and adenocarcinoma in a blinded fashion. RNA, complementary DNA and quantitative PCR. RNA was isolated from whole cells using the Qiagen microRNA extraction kit following the manufacturer's instructions. RNA was quantified spectrophotometrically, and complementary DNA was reverse-transcribed using the cDNA archival kit (Applied Biosystems) following the manufacturer's guidelines. All primers were obtained from Applied Biosystem. The cDNA samples were subjected to 40 cycles of amplification in an ABI Prism 7900 Sequence Detection System instrument according to the manufacturer's protocol. Quantification of relative messenger RNA expression was determined by the comparative C t (critical threshold) method as described whereby the amount of target mRNA, normalized to endogenous cycles of amplification was determined by the formula 2 2DDCt . Gene expression analyses by NanoString. Naive T cells from wild-type, Tim3
Tg and Tim3
Tg Ceacam1 2/2 mice were transferred into Ceacam1 2/2 Rag2 2/2 recipients to induce colitis. For the analyses of transcriptional regulation, colonic infiltrating lamina propria mononuclear cells were isolated at 6 weeks after T-cell transfer and immediately lysed in RLT buffer (Qiagen). For RNA analysis, 100 ng of total RNA was used and hybridized to a custom designed gene CodeSet (non-enzymatic RNA profiling using bar-coded fluorescent probes) according to the manufacturers protocol (Nanostring Technologies). Barcodes were counted (1,150 fields of view per sample) on an nCounter Digital Analyzer following the manufacturer's protocol (NanoString Technologies, Inc.). Cytokine measurements. To measure cytokine production by ELISA, 1 3 10 5 CD4
1 T cells were cultured in 200 ml RPMI 1640 (Sigma-Aldrich) supplemented with 10% heat-inactivated FBS, 500 U ml 21 penicillin, 100 mg ml 21 streptomycin (SigmaAldrich), 10 mM HEPES, 1% nonessential amino acids and 50 mM 2-mercaptoethanol (Life Technologies Invitrogen), which was termed complete RPMI 1640, in the presence of 5 mg ml 21 plate-bound anti-CD3 and 2 mg ml 21 soluble anti-CD28 monoclonal antibodies on flat-bottom 96-well plates (Costar), at 37 uC in a humidified atmosphere incubator containing 5% CO 2 for 48 h or otherwise indicated. Culture supernatants were removed and analysed for the production of cytokines such as IFN-c, IL-2 or TNF-a. Cytokine concentrations were determined using specific ELISAs (R&D Systems) according to the manufacturer's recommendations. To measure cytokine production by intracellular cytokine staining on colitis-associated CD4 1 T cells obtained from the dissection of mesenteric lymph nodes, lymph nodes or lamina propria were incubated at 37 uC for 4-6 h in complete RPMI 1640 medium with 50 ng ml 21 PMA (Sigma-Aldrich), 500 ng ml 21 ionomycin (Sigma-Aldrich), and 1 ml ml 21 GolgiPlug (BD). Surface staining was performed for 30 min, after which the cells were resuspended in fixation/permeabilization solution (Cytofix/ Cytoperm kit; BD). Intracellular cytokine staining using antibodies as described earlier was performed according to the manufacturer's instructions. To measure cytokine production by intracellular cytokine staining in draining lymph node CD4 Surface plasmon resonance. Studies were performed on Biacore 3000 (GE Healthcare). GST-hTIM-3 protein, or GST alone as control, was immobilized on a CM5 sensor chip using amine coupling chemistry as per the manufacturer's instructions. The coupling was performed by injecting 30 mg ml 21 of protein into 10 mM sodium acetate, pH 5.0 (GE Healthcare). HBS-EP buffer (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.005% surfactant P20; GE Healthcare) was used as running buffer and dilution buffer. Serial dilutions of analytes in HBS-EP were injected at 25 uC with a 25 ml min 21 flow rate and data collected over time. The surface was regenerated between different dilutions with 10 mM glycine-HCl, pH 2.5 (GE Healthcare). For blockade of single-chain binding to GST-hTIM-3, single-chain hCEACAM1-hTIM-3 protein was injected alone or together with antibody (anti-human CEACAM1 monoclonal antibody, 26H7) or TIM-3-specific peptide (residues 58-77, 58-CPV FECGNVVLRTDERDVNY-77) with IgG1 mouse antibody or scrambled peptide (TLCVCFVNPYDVRVNDEREG) used as controls, respectively. All data were zero adjusted, and the reference cell value was subtracted. Isolation of lamina propia mononuclear cells and TILs. Colonic lamina propria mononuclear cells, colonic polyp-derived TILs and subcutaneous CT26 derived TILs were isolated as follows. Total colons from each group were longitudinally cut and washed with HBSS (free of Ca 21 and Mg
21
) to remove faeces and debris. Subcutaneous CT26 tumours were dissected and dissociated in a gentle MACS dissociator (Miltenyi Biotec). Tumours, tumour-free colon pieces and CT26 tumour pieces were further finely minced and incubated in HBSS containing 5 mM EDTA, 0.145 mg ml 21 dithiothreitol, 1 M HEPES, 10% FBS, and 1% penicillin/streptomycin at 37 uC for 15 min for two cycles to dissociate the epithelial monolayers. EDTA was then removed by three washes in HBSS. The colon tissue and tumour specimens then were digested in RPMI 1640 containing 0.4 mg ml 21 collagenase D (Roche) and 0.01 mg ml 21 DNase I (Roche) for 20 min (tumour-free colon pieces) or 30 min (tumour pieces) at 37 uC on a shaking platform and further digested with collagenase IV (Roche) at 0.01 mg ml 21 DNase I (Roche) for 20 min (tumour-free colon pieces) or 30 min (tumour pieces) at 37 uC on a shaking platform. After enzymatic treatment, digested tissue was passed through a 70-mm cell strainer and the flow-through medium containing the mononuclear cells was collected and centrifuged at 400g for 10 min and pelleted and subjected to a 40:80% Percoll (GE Healthcare) gradient followed by centrifugation for 20 min at 2,500 r.p.m. at room temperature. Lamina propria mononuclear cells or TILs were collected at the interphase of the gradient, washed once, and resuspended in RPMI 1640 complete medium for further analyses. Statistical methods. Standard two-tailed t-test was applied throughout except for the following exceptions. A Welch t-test was applied in the setting of unequal variance. The Mann-Whitney U test was applied when data were demonstrated to not follow a Gaussian distribution. In experiments where more than two groups were compared, one-way analysis of variance (ANOVA) was performed followed by application of post-hoc correction using Bonferroni's multiple comparison test or Dunnett's correction followed by Friedman test. Kruskal-Wallis with post-hoc Dunn's correction was used in making multiple comparisons of groups with unequal size. Comparisons of mortality were made by Kaplan-Meier survival curve analysis with log-rank test to assess differences in cancer survival. Pearson's coefficient for correlation (r) test was performed for comparison of variables. GraphPad Prism version 5.0b was used for calculations. P values of 0.05 were considered significant. Pymol. e, Sequence alignment of the IgV-like domains of mCEACAM1 and mTIM-3 on the basis of the secondary structure alignment in d. f, Sequence alignments of IgV domain sequences of CEACAM1 and overall mTIM and hTIM family members. a helices (orange) and b strands (blue) denoted as underlined segments in hCEACAM1 and mTIM-3. b strands labelled with upper-and lower-case letters for hCEACAM1 and mTIM-3, respectively. Conserved residues are shaded red. Mutated residues are shaded violet for hCEACAM1, and green for hTIM-3. Asterisk (*) indicates positions having a single, fully conserved residue; a dagger ({) indicates conservation between groups of weakly similar residues; a double-dagger ({) indicates conservation between groups of strongly similar residues. g, Computational modelling as defined by energy calculations (score) relative to r.m.s. values of docking models to define potential cis and trans interfaces between mCEACAM1 and mTIM-3 as described in Supplementary Information and amino acids involved. h, CEACAM1 expression on mouse fibroblast 3T3 cells used to identify a galectin-9-independent ligand. i, CEACAM1 expression on mouse TK-1 cells as in a-c. Representative of three (a-c, h, i) independent experiments.
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Extended Data Figure 6 | CEACAM1 and TIM-3 cooperatively regulate inflammation and anti-tumour immunity. a, Representative haematoxylin and eosin staining of groups described in Fig. 3e . Scale bar, 50 mm. b, Flow cytometry for intracellular cytokine assessment of TNF-a expression from infiltrating CD4 1 T cells from inflamed colonic lamina propria of Ceacam1 2/2 Rag2 2/2 recipients, 6 weeks after transfer with naive CD4 1 CD44 lo CD62L high T cells from indicated genotypes. c, Anorectal prolapse of indicated genotypes. d, Representative haematoxylin and eosin staining of groups described in Fig. 3g . Scale bar, 50 mm. e, RNA expression defined by nanostring of lamina propria mononuclear cells in indicated groups (mean of n 5 3 per group). f, Schematic overview of protocol for AOM/DSS colitisassociated cancer model. g, Representative haematoxylin and eosin staining of colon from wild-type mice in AOM/1.5% DSS model. Scale bar, 50 mm; h, Representative photograph of distal colons of wild-type mice (n 5 3 per group, anorectal junction at left end) in AOM/1.5% DSS model. Vertical arrows show the sites for dissection of the polyps (black) and the vicinity of the polyps (red). i, Representative flow cytometry analyses on infiltrating lymphocytes of invading distal colonic polyps or from the vicinity of the polyps or from mesenteric lymph nodes for CD4 1 and CD8 1 T cells and expression of CEACAM1 and TIM-3 or PD-1 and TIM-3. Note that vicinity of polyps exhibit highest numbers of T cells with an exhausted phenotype. j, Summary of flow cytometry on infiltrating lymphocytes from invading distal colonic polyps or from vicinity of polyps and from mesenteric lymph nodes for CD4 1 and CD8 1 T cells expressing CEACAM1 and TIM-3 or PD-1 and TIM-3 (n 5 3, median shown). k, Representative pathology in AOM/1.5% DSS model. Scale bar, 60 mm. HGD, high grade dysplasia. Representative of three independent experiments (a-e, g-k).
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In this Letter, we published the crystal structure of a heterodimer of the human (h)CEACAM1 IgV domain and hTIM-3 IgV domain (Protein Data Bank (PDB) accession 4QYC). Since publication, E. Sundberg and S. Almo have questioned our model, and stated that they had obtained better results refining a hCEACAM1-hCEACAM1 homodimer model against our diffracted amplitudes. We confirm that a homodimer model indeed fits our crystallographic data better, as judged by most statistical measures (see Supplementary Table 1) . We have therefore withdrawn the deposited heterodimer model (PDB code 4QYC) from the PDB, and replaced it with a more accurate homodimer model (PDB code 5DZL). We thank E. Sundberg and S. Almo for bringing this to our attention, and apologize for any confusion the original structure may have caused.
Our error was rooted in an assumption, which now seems to be invalid, that a crystal of a chimaeric two-domain protein should give X-ray diffraction data reflecting both domains. We sought evidence for the hTIM-3 domain in our data using multiple molecular replacement and crystallographic strategies, and also reprocessed the data using lower symmetry space groups in case the hTIM-3 signal was lost in the computational averaging. We now believe that the relatively low resolution of the dataset (3.4 Å) and the similarities between the folds of hCEACAM1 and hTIM-3 make it impossible to model the hTIM-3 IgV domain confidently using the data at hand. To understand how dimeric hCEACAM1 could predominate in a crystal built from a protein construct designed to ensure a 1:1 ratio of hCEACAM1 and hTIM-3, we performed western blot analyses on the materials used for crystallization, which showed a predominant species of ~26 kDa, consistent with intact chimaeric protein and minor additional lower molecular mass species, suggesting proteolysis as the reason for the absence of hTIM-3, consistent with the long time (months) required for crystal growth (Supplementary Fig. 1 ). Considering the strong tendency of CEACAM1 to crystallize as dimers, even a small amount of free homodimer could have preferentially crystallized.
In light of this, it is important to consider whether the incorrect structure calls into question any of the other results and conclusions of the paper. Presumably, the chimaeric protein used in our Letter was unaffected because the conditions did not favour proteolysis. Nevertheless, we felt obliged to extend our biophysical experiments to provide additional support for a direct interaction between hCEACAM1 and hTIM-3. Co-crystallization attempts with hCEACAM1 and hTIM-3 would be hindered by the tendency of CEACAM1 to homodimerize with a dissociation constant (K d ) of 450 nM (ref. 1). We instead pursued NMR and surface plasmon resonance (SPR) studies using purified tag-free IgV domains of hTIM-3 and hCEACAM1 (Supplementary Methods and Supplementary  Fig. 2a-c) . NMR 15 N-HSQC spectra of 15 N-labelled hCEACAM1 IgV domains showed spectral changes after incubation with unlabelled hTIM-3 IgV in the presence of 2 mM calcium ( Supplementary Fig. 3a) , which binds to the FG loop of hTIM-3 IgV ( Supplementary Fig. 3b) ; calcium alone did not induce spectral changes in the 15 N-labelled hCEACAM1 15 N-HSQC spectra ( Supplementary Fig. 2d ). So far, hCEACAM1 dimerization and oligomerization at experimental concentrations for NMR prevent us from mapping the spectral changes to the putative hTIM-3 binding site on the GFCC′ face of hCEACAM1. We also performed SPR experiments in which we immobilized hCEA-CAM1 IgV and flowed over hTIM-3 IgV plus calcium at varying concentrations. In the initial SPR experiments, 250 response units (RU) of hCEACAM1 IgV protein were directly immobilized via amine coupling and resulted in low levels of the hTIM-3 receptive surface (B max < 10%), probably due to misoriented and dimeric immobilized hCEACAM1. Global fit analysis of the hTIM-3 binding sensorgrams to a 1:1 Langmuir binding model ( Supplementary Fig. 3c, top) yielded an underestimated association rate, an overestimated slow disassociation rate, and an overall K d value of 2.2 μ M (Supplementary Table 2 ). Further SPR studies used an oriented strategy in which C-terminal biotinylated hCEACAM1 IgV was immobilized at predominantly monomeric concentrations to a neutravidin-coupled biosensor chip, allowing CEACAM1 N-termini to be directed toward the solution. Single cycle kinetic studies were performed with serial hTIM-3 concentrations and both improved kinetic fit analysis and extrapolated steady-state analysis were performed using a 1:1 Langmuir binding model ( Supplementary Fig. 3d and Supplementary Table 2), which yielded similar affinity constants (2-6 μM) to that obtained with the amine coupling experiments.
In conclusion, our new solution-based NMR and surface-based SPR studies provide further independent biophysical evidence to support a direct interaction between hCEACAM1 and hTIM-3 via their N-terminal IgV domains. After withdrawal of our crystallographic model, we cannot confidently state the stoichiometry, describe the molecular details, or differentiate between cis/trans modes of IgV domain interaction, as claimed in Letter. Future studies are needed to determine whether the interaction may be further facilitated by additional factors or by higher order oligomerization of hCEACAM1.
We also provide a corrected version of Fig. 2i (as Supplementary Fig. 3e to this Corrigendum), which during the review process inadvertently duplicated the left panel of the autoradiogram.
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